Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DJFLI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
T-Ed9
|
|||||
| Synonyms |
T-Ed9; Tras-GGFG-Ed9
Click to Show/Hide
|
|||||
| Organization |
Zhejiang university.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Ed9
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Cysteine-maleimide conjugation
|
|||||
| Combination Type |
Mc-GGFG-Ed9
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.091 nM
|
|||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.331 nM
|
|||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
References